Difference between revisions of "Vascular sarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 50%; text-align:center;"" to "{| class="wikitable" style="width: 40%; text-align:center;"") |
Warner-admin (talk | contribs) m (Text replacement - "|Phase II" to "|Phase 2") |
||
| Line 38: | Line 38: | ||
|- | |- | ||
|[https://doi.org/10.1093/annonc/mds237 Agulnik et al. 2013 (NU 04S1)] | |[https://doi.org/10.1093/annonc/mds237 Agulnik et al. 2013 (NU 04S1)] | ||
| − | | style="background-color:#91cf61" |Phase | + | | style="background-color:#91cf61" |Phase 2 |
|- | |- | ||
|} | |} | ||
| Line 62: | Line 62: | ||
|- | |- | ||
|[https://doi.org/10.1200/jco.2008.17.3146 Penel et al. 2008 (ANGIOTAX)] | |[https://doi.org/10.1200/jco.2008.17.3146 Penel et al. 2008 (ANGIOTAX)] | ||
| − | | style="background-color:#91cf61" |Phase | + | | style="background-color:#91cf61" |Phase 2 |
|- | |- | ||
|} | |} | ||
Revision as of 17:52, 12 February 2022
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN  ejdavis25
|
0 regimens on this page
0 variants on this page
|
- Note: this page contains regimens for several subtypes of vascular sarcoma. The following links will take you to disease-specific pages:
- Regimens for Kaposi sarcoma are here.
Guidelines
ESMO
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) PubMed
NCCN
Angiosarcoma, all lines of therapy
Bevacizumab monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Agulnik et al. 2013 (NU 04S1) | Phase 2 |
Targeted therapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
References
- NU 04S1: Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. link to original article contains verified protocol PubMed NCT00288015
Paclitaxel monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Penel et al. 2008 (ANGIOTAX) | Phase 2 |
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
Supportive medications
- Dexamethasone (Decadron) 8 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- Cimetidine (Tagamet) 200 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- Dexchlorpheniramine (Polaramine) 5 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- "Standard antiemetics (mainly Metoclopramide (Reglan)) were prescribed as clinically indicated by the treating physician"
28-day cycle for 6 cycles
References
- ANGIOTAX: Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. link to original article contains verified protocol PubMed